Mindray (迈瑞医疗) A+H Pre-IPO: Early Thoughts
Mindray is seeking to raise at least USD500m through an A+H listing. The note covers business quality, industry context, peer valuation, and A-H...
156 Views
CSPC Pharma (1093 HK): 1Q26 Revenue Down, Regular Approvals and New Launches Hold Key For Future
CSPC Pharma's 1Q26 revenue declined as finished drugs dragged. Recent $1.2B upfront payment from AstraZeneca will help boost upcoming quarters....
127 Views
2018 HK-Connect SouthBound In a Nutshell
Since autumn of 2014, the HK-Shanghai Connect, and later the HK-Shenzhen Connect mechanisms have provided means for mainland investors to buy Hong...
874 Views
Quiddity Weekly H/A: Spread Monitor & Southbound Flows [Week to 29 Jun 2018]
An H/A Spread Monitor Project offering a brief look at recent changes in H-Share and A-Share spreads, Southbound flow and impact, and where the...
364 Views
CSPC Pharma (1093 HK): 2025 Witness VBP Inclusion Impact; Pipeline and Launches Hold Key For Future
CSPC Pharma's 2025 revenue dropped 10% YoY due to finished drugs decline. Focus on new products, pipeline strength, and high-end market expansion...
201 Views